Protein Phosphorylation in Cancer: Role of Nitric Oxide Signaling Pathway

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Aug 6

PMID 34356634

Citations 28

Authors

Xinran Liu

Yiping Zhang

Yijie Wang

Meiwen Yang

Fenfang Hong

Shulong Yang

Affiliations

Soon will be listed here.

Abstract

Nitric oxide (NO), a free radical, plays a critical role in a wide range of physiological and pathological processes. Due to its pleiotropic function, it has been widely investigated in various types of cancers and is strongly associated with cancer development. Mounting pieces of evidence show that NO regulates various cancer-related events, which mainly depends on phosphorylating the key proteins in several signaling pathways. However, phosphorylation of proteins modulated by NO signaling pathway may lead to different effects in different types of cancer, which is complex and remains unclear. Therefore, in this review, we focus on the effect of protein phosphorylation modulated by NO signaling pathway in different types of cancers including breast cancer, lung cancer, prostate cancer, colon cancer, gastric cancer, pancreatic cancer, ovarian cancer, and neuroblastoma. Phosphorylation of key proteins, including p38 MAPK, ERK, PI3K, STAT3, and p53, modified by NO in various signaling pathways affects different cancer-related processes including cell apoptosis, proliferation, angiogenesis, metastasis, and several cancer therapies. Our review links the NO signaling pathway to protein phosphorylation in cancer development and provides new insight into potential targets and cancer therapy.

Citing Articles

Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma.

Zhang P, Wang D, Zhou G, Jiang S, Zhang G, Zhang L J Immunother Cancer. 2025; 13(2).

PMID: 40010763 PMC: 11865799. DOI: 10.1136/jitc-2024-010787.

Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia.

Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C Molecules. 2025; 30(3).

PMID: 39942749 PMC: 11820228. DOI: 10.3390/molecules30030645.

Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer.

Bruno P, Arshad A, Gogu M, Waterman N, Flack R, Dunn K Life (Basel). 2025; 15(1).

PMID: 39860065 PMC: 11766951. DOI: 10.3390/life15010126.

Development and experimental validation of dephosphorylation-related biomarkers to assess prognosis and immunotherapeutic response in gliomas.

Tang H, Yang X, Li G, Peng K, Sun Y, Jiang L Front Immunol. 2025; 15():1488894.

PMID: 39830513 PMC: 11739095. DOI: 10.3389/fimmu.2024.1488894.

Targeting protein modification: a new direction for immunotherapy of pancreatic cancer.

Ge X, Zhang K, Zhu J, Chen Y, Wang Z, Wang P Int J Biol Sci. 2025; 21(1):63-74.

PMID: 39744438 PMC: 11667816. DOI: 10.7150/ijbs.101861.

References

Paik J, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z . FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007; 128(2):309-23. PMC: 1855089. DOI: 10.1016/j.cell.2006.12.029. View

Alimoradi H, Greish K, Gamble A, Giles G . Controlled Delivery of Nitric Oxide for Cancer Therapy. Pharm Nanotechnol. 2019; 7(4):279-303. PMC: 6967185. DOI: 10.2174/2211738507666190429111306. View

Hundley T, Rigas B . Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J Pharmacol Exp Ther. 2005; 316(1):25-34. DOI: 10.1124/jpet.105.091363. View

Kamm A, Przychodzen P, Kuban-Jankowska A, Jacewicz D, Dabrowska A, Nussberger S . Nitric oxide and its derivatives in the cancer battlefield. Nitric Oxide. 2019; 93:102-114. DOI: 10.1016/j.niox.2019.09.005. View

Wang J, He P, Gaida M, Yang S, Schetter A, Gaedcke J . Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Oncotarget. 2016; 7(33):52993-53004. PMC: 5288163. DOI: 10.18632/oncotarget.10323. View

Crane B, Arvai A, Ghosh D, Wu C, Getzoff E, Stuehr D . Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science. 1998; 279(5359):2121-6. DOI: 10.1126/science.279.5359.2121. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Tyryshkin A, Gorgun F, Abdel Fattah E, Mazumdar T, Pandit L, Zeng S . Src kinase-mediated phosphorylation stabilizes inducible nitric-oxide synthase in normal cells and cancer cells. J Biol Chem. 2009; 285(1):784-92. PMC: 2804227. DOI: 10.1074/jbc.M109.055038. View

Frederiksen L, Sullivan R, Maxwell L, Macdonald-Goodfellow S, Adams M, Bennett B . Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res. 2007; 13(7):2199-206. DOI: 10.1158/1078-0432.CCR-06-1807. View

10.

Behrens A, Sibilia M, Wagner E . Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999; 21(3):326-9. DOI: 10.1038/6854. View

11.

Ha K, Kim K, Kwon Y, Bai S, Nam W, Yoo Y . Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J. 2003; 17(9):1036-47. DOI: 10.1096/fj.02-0738com. View

12.

Zhao X, Cai A, Peng Z, Liang W, Xi H, Li P . JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer. J Cell Mol Med. 2019; 23(4):2489-2504. PMC: 6433691. DOI: 10.1111/jcmm.14122. View

13.

Choudhari S, Chaudhary M, Bagde S, Gadbail A, Joshi V . Nitric oxide and cancer: a review. World J Surg Oncol. 2013; 11:118. PMC: 3669621. DOI: 10.1186/1477-7819-11-118. View

14.

Stewart G, Nanda J, Brown D, Riddick A, Ross J, Habib F . NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2008; 124(1):223-32. DOI: 10.1002/ijc.23934. View

15.

Kim J, Yung B, Kim W, Chen X . Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy. J Control Release. 2016; 263:223-230. PMC: 5484762. DOI: 10.1016/j.jconrel.2016.12.026. View

16.

Singh V, Ram M, Kumar R, Prasad R, Roy B, Singh K . Phosphorylation: Implications in Cancer. Protein J. 2017; 36(1):1-6. DOI: 10.1007/s10930-017-9696-z. View

17.

Ferrandina G, Legge F, Martinelli E, Ranelletti F, Zannoni G, Lauriola L . Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer. 2005; 92(2):271-7. PMC: 2361852. DOI: 10.1038/sj.bjc.6602332. View

18.

Menon S, Goswami P . A redox cycle within the cell cycle: ring in the old with the new. Oncogene. 2006; 26(8):1101-9. DOI: 10.1038/sj.onc.1209895. View

19.

Ridnour L, Barasch K, Windhausen A, Dorsey T, Lizardo M, Yfantis H . Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS One. 2012; 7(9):e44081. PMC: 3434220. DOI: 10.1371/journal.pone.0044081. View

20.

Monteiro H, Costa P, Reis A, Stern A . Nitric oxide: Protein tyrosine phosphorylation and protein S-nitrosylation in cancer. Biomed J. 2015; 38(5):380-8. DOI: 10.4103/2319-4170.158624. View